108 related articles for article (PubMed ID: 18206988)
1. Investigating the biomarker potential of glycoproteins using comparative glycoprofiling - application to tissue inhibitor of metalloproteinases-1.
Thaysen-Andersen M; Thøgersen IB; Lademann U; Offenberg H; Giessing AM; Enghild JJ; Nielsen HJ; Brünner N; Højrup P
Biochim Biophys Acta; 2008 Mar; 1784(3):455-63. PubMed ID: 18206988
[TBL] [Abstract][Full Text] [Related]
2. Rapid and individual-specific glycoprofiling of the low abundance N-glycosylated protein tissue inhibitor of metalloproteinases-1.
Thaysen-Andersen M; Thøgersen IB; Nielsen HJ; Lademann U; Brünner N; Enghild JJ; Højrup P
Mol Cell Proteomics; 2007 Apr; 6(4):638-47. PubMed ID: 17205978
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer.
Hilska M; Roberts PJ; Collan YU; Laine VJ; Kössi J; Hirsimäki P; Rahkonen O; Laato M
Int J Cancer; 2007 Aug; 121(4):714-23. PubMed ID: 17455256
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase 2 and tissue inhibitor of matrix metalloproteinases 2 in the diagnosis of colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Gryko M; Kędra B; Szmitkowski M
Folia Histochem Cytobiol; 2010 Dec; 48(4):564-71. PubMed ID: 21478099
[TBL] [Abstract][Full Text] [Related]
5. Identifying N-Glycan Biomarkers in Colorectal Cancer by Mass Spectrometry.
Sethi MK; Hancock WS; Fanayan S
Acc Chem Res; 2016 Oct; 49(10):2099-2106. PubMed ID: 27653471
[TBL] [Abstract][Full Text] [Related]
6. The presence of outer arm fucose residues on the N-glycans of tissue inhibitor of metalloproteinases-1 reduces its activity.
Kim HIe; Saldova R; Park JH; Lee YH; Harvey DJ; Wormald MR; Wynne K; Elia G; Kim HJ; Rudd PM; Lee ST
J Proteome Res; 2013 Aug; 12(8):3547-60. PubMed ID: 23815085
[TBL] [Abstract][Full Text] [Related]
7. Plasma TIMP-1 and CEA in detection of primary colorectal cancer: a prospective, population based study of 4509 high-risk individuals.
Nielsen HJ; Brünner N; Jorgensen LN; Olsen J; Rahr HB; Thygesen K; Hoyer U; Laurberg S; Stieber P; Blankenstein MA; Davis G; Dowell BL; Christensen IJ; ;
Scand J Gastroenterol; 2011 Jan; 46(1):60-9. PubMed ID: 20799911
[TBL] [Abstract][Full Text] [Related]
8. Plasma TIMP-1 and CEA as Markers for Detection of Primary Colorectal Cancer: A Prospective Validation Study Including Symptomatic and Non-symptomatic Individuals.
Christensen IJ; Brünner N; Dowell B; Davis G; Nielsen HJ; Newstead G; King D
Anticancer Res; 2015 Sep; 35(9):4935-41. PubMed ID: 26254391
[TBL] [Abstract][Full Text] [Related]
9. Salivary tissue inhibitor of metalloproteinases-1 localization and glycosylation profile analysis.
Holten-Andersen L; Thaysen-Andersen M; Jensen SB; Buchwald C; Højrup P; Offenberg H; Nielsen HJ; Brünner N; Nauntofte B; Reibel J
APMIS; 2011 Nov; 119(11):741-9. PubMed ID: 21995626
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
[TBL] [Abstract][Full Text] [Related]
11. N-glycomic profiling of colorectal cancer according to tumor stage and location.
Holm M; Nummela P; Heiskanen A; Satomaa T; Kaprio T; Mustonen H; Ristimäki A; Haglund C
PLoS One; 2020; 15(6):e0234989. PubMed ID: 32598367
[TBL] [Abstract][Full Text] [Related]
12. Biology and potential clinical implications of tissue inhibitor of metalloproteinases-1 in colorectal cancer treatment.
Møller Sørensen N; Vejgaard Sørensen I; Ørnbjerg Würtz S; Schrohl AS; Dowell B; Davis G; Jarle Christensen I; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(7):774-86. PubMed ID: 18584515
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry.
Ahn YH; Lee JY; Lee JY; Kim YS; Ko JH; Yoo JS
J Proteome Res; 2009 Sep; 8(9):4216-24. PubMed ID: 19645485
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Schrohl AS; Mueller V; Christensen IJ; Pantel K; Thomssen C; Bruenner N
Tumour Biol; 2008; 29(3):181-7. PubMed ID: 18645261
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
16. TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer: A meta-analysis.
Meng C; Yin X; Liu J; Tang K; Tang H; Liao J
PLoS One; 2018; 13(11):e0207039. PubMed ID: 30458003
[TBL] [Abstract][Full Text] [Related]
17. Saliva and plasma TIMP-1 in patients with colorectal cancer: a prospective study.
Holten-Andersen L; Christensen IJ; Jensen SB; Reibel J; Laurberg S; Nauntofte B; Brünner N; Nielsen HJ
Scand J Gastroenterol; 2012 Oct; 47(10):1234-41. PubMed ID: 22871105
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
19. Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases 1 in plasma by immunoassay.
Holten-Andersen MN; Christensen IJ; Nielsen HJ; Lilja H; Murphy G; Jensen V; Brünner N; Piironen T
Clin Chem; 2002 Aug; 48(8):1305-13. PubMed ID: 12142388
[TBL] [Abstract][Full Text] [Related]
20. In-depth N-glycome profiling of paired colorectal cancer and non-tumorigenic tissues reveals cancer-, stage- and EGFR-specific protein N-glycosylation.
Sethi MK; Kim H; Park CK; Baker MS; Paik YK; Packer NH; Hancock WS; Fanayan S; Thaysen-Andersen M
Glycobiology; 2015 Oct; 25(10):1064-78. PubMed ID: 26085185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
